Q: What is ravulizumab used for?

Ravulizumab is used to treat: Paroxysmal nocturnal hemoglobinuria Atypical hemolytic uremic syndrome

Q: How does ravulizumab work?

The Complement System Ravulizumab belongs to a class of medicines known as complement inhibitors. The complement system is a group of proteins in the blood that are part of the body's natural immune response. While this system usually helps fight off bacteria and viruses, in certain medical conditions, it can become overactive and begin attacking the body's own healthy cells. Targeting the C5 Protein This medication works by specifically binding to a protein called C5. By attaching to this protein, ravulizumab prevents it from breaking down into other substances that trigger inflammation and cell destruction. This process is often referred to as blocking the complement cascade. How It Helps Specific Conditions By inhibiting the complement system, ravulizumab helps manage several different disorders: Paroxysmal Nocturnal Hemoglobinuria (PNH): It prevents the immune system from breaking down red blood cells too quickly. Atypical Hemolytic Uremic Syndrome (aHUS): It stops the immune system from creating tiny blood clots that can damage the kidneys and other organs. Generalized Myasthenia Gravis (gMG) and NMOSD: It reduces the immune-mediated attack on the nervous system and muscles, which helps improve strength and reduce symptoms. Ravulizumab is designed to stay in the body for a long time, which allows for a longer period between treatments compared to some other similar medications.

Q: What are the brand names for ravulizumab?

ravulizumab is sold under the brand name Ultomiris .

Q: What are the active ingredients in ravulizumab?

The active ingredient in ravulizumab is ravulizumab .

Q: What are the side effects of ravulizumab?

Common side effects of ravulizumab may include: Headache Upper respiratory tract infection Nausea Always consult with a healthcare professional about potential side effects.

Q: What drug class is ravulizumab?

ravulizumab belongs to the complement C5 inhibitor drug class.

Q: What is the dosage of ravulizumab and how do I take it?

Administration Methods Ravulizumab is available in two forms: an intravenous (IV) infusion and a subcutaneous injection. The method used depends on the specific condition being treated and the patient's weight. Intravenous Infusion When given intravenously, a healthcare professional administers the medication into a vein. This process usually takes a specific amount of time depending on the dose and the patient's weight. These infusions are typically performed in a hospital, clinic, or infusion center. Subcutaneous Injection The subcutaneous form is injected under the skin, usually in the abdomen or thigh. In some cases, a healthcare provider may train a patient or caregiver to administer these injections at home using a specialized delivery system or on-body injector. Dosing Schedule Treatment generally begins with a starting dose, often called a loading dose. Following this, maintenance doses are given at regular intervals. The frequency of these doses is determined by a doctor based on the patient's weight and the condition being treated. It is important to follow the schedule exactly as prescribed by a healthcare professional. Missed Doses It is important to receive every scheduled dose of ravulizumab. If an appointment for an infusion is missed or if a self-administered dose is skipped, contact a healthcare provider right away to reschedule or receive instructions on how to proceed. Do not administer extra medication to make up for a missed dose.

Q: Is ravulizumab safe during pregnancy and breastfeeding?

Pregnancy There is limited information regarding the safety of ravulizumab use during pregnancy. Because ravulizumab is a monoclonal antibody, it is expected to cross the placental barrier and reach the developing fetus. Animal studies have indicated potential risks to fetal development, but adequate and well-controlled studies in humans are currently unavailable. If you are pregnant or planning to become pregnant, it is important to discuss the potential benefits of treatment against the possible risks to the fetus with your doctor. Healthcare providers typically evaluate whether the clinical need for the medication outweighs the potential risks. Breastfeeding It is currently unknown whether ravulizumab passes into human breast milk. There is also no data available regarding the medication's effects on a breastfed infant or its impact on milk production. Because many drugs are excreted in human milk and the potential for serious adverse reactions in nursing infants is unknown, you should consult your healthcare provider before breastfeeding while using this medication.

Q: What forms and strengths does ravulizumab come in?

Ravulizumab is provided in the following forms: Intravenous Infusion: A concentrated solution that is diluted and administered into a vein by a healthcare professional. Subcutaneous Injection: A solution administered under the skin using a specialized on-body delivery system.

Question 1

What is ravulizumab?

Accepted Answer

Ravulizumab is a monoclonal antibody designed to function as a complement inhibitor. It works by binding to a specific protein in the immune system to prevent the overactivation of certain biological pathways.

By inhibiting these specific immune responses, the medication helps protect cells from damage caused by the body's own defense system. This targeted approach helps maintain the stability of the immune environment.

Question 2

What is ravulizumab used for?

Accepted Answer

Ravulizumab is used to treat:

Paroxysmal nocturnal hemoglobinuria
Atypical hemolytic uremic syndrome

Question 3

How does ravulizumab work?

Accepted Answer

The Complement System

Ravulizumab belongs to a class of medicines known as complement inhibitors. The complement system is a group of proteins in the blood that are part of the body's natural immune response. While this system usually helps fight off bacteria and viruses, in certain medical conditions, it can become overactive and begin attacking the body's own healthy cells.

Targeting the C5 Protein

This medication works by specifically binding to a protein called C5. By attaching to this protein, ravulizumab prevents it from breaking down into other substances that trigger inflammation and cell destruction. This process is often referred to as blocking the complement cascade.

How It Helps Specific Conditions

By inhibiting the complement system, ravulizumab helps manage several different disorders:

Paroxysmal Nocturnal Hemoglobinuria (PNH): It prevents the immune system from breaking down red blood cells too quickly.
Atypical Hemolytic Uremic Syndrome (aHUS): It stops the immune system from creating tiny blood clots that can damage the kidneys and other organs.
Generalized Myasthenia Gravis (gMG) and NMOSD: It reduces the immune-mediated attack on the nervous system and muscles, which helps improve strength and reduce symptoms.

Ravulizumab is designed to stay in the body for a long time, which allows for a longer period between treatments compared to some other similar medications.

Question 4

What are the brand names for ravulizumab?

Accepted Answer

ravulizumab is sold under the brand name Ultomiris.

Question 5

What are the active ingredients in ravulizumab?

Accepted Answer

The active ingredient in ravulizumab is ravulizumab.

Question 6

What are the side effects of ravulizumab?

Accepted Answer

Common side effects of ravulizumab may include:

Headache
Upper respiratory tract infection
Nausea

Always consult with a healthcare professional about potential side effects.

Question 7

What drug class is ravulizumab?

Accepted Answer

ravulizumab belongs to the complement C5 inhibitor drug class.

Question 8

What is the dosage of ravulizumab and how do I take it?

Accepted Answer

Administration Methods

Ravulizumab is available in two forms: an intravenous (IV) infusion and a subcutaneous injection. The method used depends on the specific condition being treated and the patient's weight.

Intravenous Infusion

When given intravenously, a healthcare professional administers the medication into a vein. This process usually takes a specific amount of time depending on the dose and the patient's weight. These infusions are typically performed in a hospital, clinic, or infusion center.

Subcutaneous Injection

The subcutaneous form is injected under the skin, usually in the abdomen or thigh. In some cases, a healthcare provider may train a patient or caregiver to administer these injections at home using a specialized delivery system or on-body injector.

Dosing Schedule

Treatment generally begins with a starting dose, often called a loading dose. Following this, maintenance doses are given at regular intervals. The frequency of these doses is determined by a doctor based on the patient's weight and the condition being treated. It is important to follow the schedule exactly as prescribed by a healthcare professional.

Missed Doses

It is important to receive every scheduled dose of ravulizumab. If an appointment for an infusion is missed or if a self-administered dose is skipped, contact a healthcare provider right away to reschedule or receive instructions on how to proceed. Do not administer extra medication to make up for a missed dose.

Question 9

Is ravulizumab safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

There is limited information regarding the safety of ravulizumab use during pregnancy. Because ravulizumab is a monoclonal antibody, it is expected to cross the placental barrier and reach the developing fetus. Animal studies have indicated potential risks to fetal development, but adequate and well-controlled studies in humans are currently unavailable.

If you are pregnant or planning to become pregnant, it is important to discuss the potential benefits of treatment against the possible risks to the fetus with your doctor. Healthcare providers typically evaluate whether the clinical need for the medication outweighs the potential risks.

Breastfeeding

It is currently unknown whether ravulizumab passes into human breast milk. There is also no data available regarding the medication's effects on a breastfed infant or its impact on milk production. Because many drugs are excreted in human milk and the potential for serious adverse reactions in nursing infants is unknown, you should consult your healthcare provider before breastfeeding while using this medication.

Question 10

What forms and strengths does ravulizumab come in?

Accepted Answer

Ravulizumab is provided in the following forms:

Intravenous Infusion: A concentrated solution that is diluted and administered into a vein by a healthcare professional.
Subcutaneous Injection: A solution administered under the skin using a specialized on-body delivery system.

Question 11

What is the FDA approval status of ravulizumab?

Accepted Answer

FDA Approval and Indications

Ravulizumab is approved by the U.S. Food and Drug Administration (FDA) for the treatment of the following conditions in adults and, in some cases, children:

Paroxysmal nocturnal hemoglobinuria (PNH).
Atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy.
Generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor (AChR) antibody-positive.
Neuromyelitis optica spectrum disorder (NMOSD) in patients who are anti-aquaporin-4 (AQP4) antibody-positive.

Boxed Warning and Safety Programs

The FDA has issued a boxed warning for ravulizumab because it increases the risk of serious and life-threatening meningococcal infections. These infections can become rapidly fatal if not recognized and treated early.

Due to this risk, the drug is only available through a restricted program called a Risk Evaluation and Mitigation Strategy (REMS). Healthcare providers must be certified in the program, and patients must be informed of the risks. Patients are generally required to receive a meningococcal vaccine at least two weeks before starting treatment, unless the need for urgent treatment outweighs the risk of delaying therapy.

Regulatory History

Ravulizumab was first approved by the FDA in 2018. It is classified as a long-acting complement inhibitor, designed to require less frequent dosing than earlier medications in its class.

Question 12

What should I know about ravulizumab and cost?

Accepted Answer

Factors Influencing Cost

The total cost of treatment with ravulizumab depends on several variables, including the specific medical condition being treated and the patient's body weight, which determines the required dosage. Because it is a biologic medication administered by healthcare professionals, costs also include the fees associated with the infusion or injection process at a hospital or clinic.

Insurance and Assistance

Insurance coverage varies by provider and plan. Many patients may have high out-of-pocket expenses, such as deductibles or coinsurance. Financial assistance programs or copay support may be available through the drug manufacturer for those who qualify based on financial need or insurance status.

Generic Options

Currently, there are no generic or biosimilar versions of ravulizumab available. Biologic drugs are complex to manufacture and are usually protected by patents for several years, which contributes to their higher cost compared to standard chemical drugs.

ravulizumab

📋Overview

How It Works

Uses

Brand Names

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for ravulizumab

Hospitals.net Disclosure